Arrowhead's ARO-MAPT shows major tau reduction in early trial
Arrowhead Pharmaceuticals' RNAi drug ARO-MAPT reduced tau protein by an average of 73% in healthy volunteers, demonstrating significant target engagement via subcutaneous dosing.
Arrowhead Pharmaceuticals' experimental RNAi drug ARO-MAPT reduced tau protein levels by an average of 73% after 105 days in a subcutaneous trial. The highest dose of 12.8 milligrams per kilogram, given in two injections two weeks apart, produced individual reductions of up to 85% in cerebrospinal fluid total tau in healthy volunteers.
Interim data from the single-ascending-dose study showed a clear dose-response relationship. Lower doses also produced significant reductions. Placebo recipients showed no change in tau levels.
| Dose (mg/kg) | Administration Schedule | Mean Tau Reduction at Day 105 |
|---|---|---|
| 2.1 | Days 1, 8, and 15 | 40% |
| 6.4 | Days 1, 8, and 15 | 69% |
| 12.8 | Days 1 and 15 | 73% |
Safety and dosing profile supports further development
ARO-MAPT was well tolerated in the approximately 64 healthy volunteers enrolled. The trial's primary focus was safety. Side effects were mild and included injection site reactions, bruising, respiratory infections, and headaches. No serious treatment-emergent adverse events were reported. Investigators observed no neurobehavioral events like confusion and no persistent anemia.
The ongoing ARO-MAPT-SC-1001 study is designed to assess safety, pharmacokinetics, and pharmacodynamic effects. Healthy-volunteer enrollment is complete. Enrollment in Alzheimer's patient cohorts is ongoing at sites in Canada, the U.K., Australia, and New Zealand.
Mechanism and platform validation
ARO-MAPT is an investigational small interfering RNA therapy designed to reduce tau protein expression in the central nervous system. Arrowhead stated the results provide clinical validation of its TRiM Platform. This technology enables drugs to reach cells outside the liver, including in the CNS.
Preclinical monkey studies showed subcutaneous administration reduced MAPT gene expression by more than 75% across multiple brain regions, including the hippocampus. Repeat dosing maintained gene silencing and supported up to 60% CSF tau knockdown four months after the last dose. The work suggested more homogeneous brain distribution than from intrathecal administration, potentially improving silencing in disease-relevant areas.
Future trials and broader implications
The rest of the trial will include both healthy volunteers and people with mild Alzheimer’s disease. Future dosing may involve up to five shots. Arrowhead stated the findings suggest the medicine could eventually be injected once every three months, enabling potential at-home dosing.
The company is planning trials in other tau-linked conditions, including frontotemporal dementia and progressive supranuclear palsy. It has begun regulatory discussions regarding potential later-stage studies in MAPT-variant frontotemporal dementia and progressive supranuclear palsy. Arrowhead aims to finalize study designs following additional regulatory discussions over the next one to two quarters.
Arrowhead plans to provide additional data from multiple-ascending-dose healthy-volunteer cohorts in 2027. An update from the Alzheimer's patient cohorts is also expected that year. The company plans to introduce at least three additional wholly owned CNS candidates into the clinic over the next 12 months.
Expert perspective on tau targeting
Analysts and researchers acknowledge the promise but highlight unknowns. Stifel analyst James Condulis wrote that the results "look compelling and, with subcutaneous delivery, arguably look better than what we’ve seen" with other drugs designed to cross the blood-brain barrier. He also cautioned that the drug is still in very early development stages and that tau has yet to be clearly proven as a good Alzheimer’s target.
Adam Boxer, a professor of neurology at the University of California, San Francisco, noted that two approved anti-amyloid therapies have shown modest slowing of cognitive decline. Tau-directed treatments may provide another way to address disease progression. He discussed prior studies of tau-targeting antisense therapies, which suggested reductions in CSF tau and signals of slowed decline.
Boxer said important questions remain regarding the optimal degree and duration of tau reduction. Tau has normal physiological roles, and evidence has not linked tau loss of function to disease. Prior clinical findings with another tau-lowering therapy raised questions about whether adverse effects could result from the treatment approach or from on-target tau reduction.
Arrowhead expects to provide additional data from multiple-ascending-dose healthy-volunteer cohorts and an update from Alzheimer's patient cohorts in 2027.
